Rezolute/$RZLT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Rezolute

Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.

Ticker

$RZLT
Primary listing

Industry

Biotechnology

Employees

68

ISIN

US76200L3096

Rezolute Metrics

BasicAdvanced
$474M
-
-$1.11
1.04
-

What the Analysts think about Rezolute

Analyst ratings (Buy, Hold, Sell) for Rezolute stock.

Bulls say / Bears say

Rezolute's lead candidate, ersodetug, has received Breakthrough Therapy Designation from the FDA for treating hypoglycemia due to tumor-induced hyperinsulinism, potentially expediting its development and approval process. (ir.rezolutebio.com)
The company successfully raised approximately $97 million in April 2025, extending its cash runway to mid-2027, which supports ongoing and future clinical trials. (ir.rezolutebio.com)
Rezolute is advancing two Phase 3 trials for ersodetug targeting different forms of hyperinsulinism, with topline results expected in the second half of 2025 and 2026, indicating a robust pipeline with significant market potential. (ir.rezolutebio.com)
Rezolute reported a net loss of $18.9 million for the third quarter of fiscal 2025, an increase from $17.1 million in the same period the previous year, reflecting rising operational expenses. (ir.rezolutebio.com)
The company's cash, cash equivalents, and investments decreased to $88.4 million as of March 31, 2025, down from $127.1 million as of June 30, 2024, indicating a significant cash burn rate. (ir.rezolutebio.com)
Despite advancing clinical programs, Rezolute has yet to generate revenue from product sales, relying heavily on external funding to sustain operations. (ir.rezolutebio.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.

Rezolute Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Rezolute Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RZLT

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs